All News

The concept of a single-payer health system remains somewhat controversial among some legislators, yet Vermont continues to embrace the transition despite the challenges.

Next year, U.S. healthcare providers will be subject to Medicare penalties if they do not meet up to 26 measures for value-based purchasing.

The study, published in the Journal of Clinical Oncology, examined national statistics for the period between 2007 to 2010 for people aged 18-64 of age.

Specialty drugs expected to account for 40% of total prescription spending by 2016, according to Catamaran Corporation.

Using the genome editing tool known as CRISPR, researchers were able to selectively silence two genes in HPV that are responsible for the growth and survival of cervical carcinoma cells.

The approval follows results from the RETRIEVE trial, conducted in patients who had previously responded to Velcade but had relapsed.

Although the overall rate of NSCLC is lower, certain subtypes of the disease fared better than others, the study published in the journal Cancer found.

New research found that the risk of developing breast cancer increased in women who had mutations of a gene related to BRCA2, the PALB2 gene.

Bottom line: Sovaldi will not save the system money. It will cost money-a lot of money-to reduce premature mortality due to chronic hepatitis C infection.

The CMS has removed the provider review version of a new database that details financial relationships between healthcare providers and drug and medical-device manufacturers.

Consumers who missed open enrollment on the state health insurance marketplaces this spring or who are waiting for employer coverage to start don't have to "go bare."

The World Health Organization declared an international public health emergency Friday over the Ebola outbreak in western Africa that has killed almost 1,000 people. The outbreak of the deadly virus is "extraordinary event" and a public health risk to other countries, it said.

Older patients who are diagnosed with HIV/AIDS present a variety of challenges for providers, especially when it comes to controlling their costs of care.

The research, published in the journal Cell, proposes revising treatment based on the molecular constitution of the tumor when it presents itself, rather than the tissue or organ of origin.

According to Sir Andrew Dillon, chief executive of NICE, the high price that Roche is demanding for Kadcyla is beyond the means of NHS to cover.

The study, published in NEJM, proposes enhanced surveillance in women with PALB2 mutations, similar to women harboring BRCA2 mutations.

High rate of hospice survivors, especially in Alabama and Mississippi, have raised doubts about improper practices.

Published in Nature Communications, the study identified a new gene fusion and rearrangement of the estrogen receptor, responsible for the aggressive nature of luminal B breast cancer.

Six of the most prominent healthcare systems in Wisconsin have created a new partnership, jumping on the nationwide bandwagon of forming strategic alliances to share information, while remaining independent.

While a few free health clinics have shut their doors in Arkansas and Washington, most expansion-state non-profit free clinics are reassessing their business strategies.

The Lancet study, conducted in Europe, found a survival benefit with early diagnosis, but does not agree that the benefit outweighs some of the associated risks of the test.

The number of young adults who are at risk for mental health problems and substance abuse are now increasingly seeking care due to a provision of the Affordable Care Act (ACA).

As health costs continue to climb, consumers are increasingly finding their care treatments abroad at nearly half the price under growing support from insurance agencies.

Comparing the cost of employer-sponsored insurance to the cost of either Medicare or Medicaid is a completely stacked comparison even if we fully adjust for every iota of age and health status differences between these three populations and use an apples-to-apples comparison of plans having the identical benefits and actuarial value.

What looks like a simple case of humanitarian goodwill could lead to some unintended and very negative consequences, experts said Tuesday.

The federal government this month quietly stopped publicly reporting when hospitals leave foreign objects in patients' bodies or make a host of other life-threatening mistakes.

The results of ruxolitinib's RESPONSE trial were recently presented at ASCO's annual meeting.

Health technology and electronic health-record powerhouse Cerner Corp. is spending $1.3 billion to purchase Siemens Health Services, Siemens' health information technology business, Cerner announced Tuesday.

Within a week of Sandoz applying for approval of it's biosimlar to Amgen's Neupogen, U.S. senators want the FDA to lay down guidelines on naming these drugs.